Activation of cGAS-STING suppressed bladder cancer in cisplatin-treated C57 mice. (A) Establish of bladder cancer transplantation models in C57 mice, left. Tumor volumes of different groups, right. (B–E) Infiltration percentages of (B) CD8+, CD45+ T cells, (C) CD11b+, MHCⅡ+ DCs, (D) F4/80+, CD11c+ Macrophage, (E) CD3+, CD45+ cells in MB49 transplantation tumors. (F–J) CYBERSORT predicted infiltration percentages of CD8+ T cells (F), DCs activated cells (G), DCs resting cells (H), Macrophages M1 cells (I), and Macrophages M2 cells (J) in response group (n = 50, CR or PR) was significantly higher than non-response group (n = 30, PD or SD) after cisplatin-based chemotherapy. * p < 0.05, ** p < 0.01, *** p < 0.001. DDP, cisplatin.